#BEGIN_DRUGCARD DB00250

# AHFS_Codes:
08:16.92

# ATC_Codes:
D10AX05
J04BA02

# Absorption:
Bioavailability is 70 to 80% following oral administration.

# Biotransformation:
Hepatic, mostly CYP2E1-mediated.

# Brand_Mixtures:
Not Available

# Brand_Names:
Aczone

# CAS_Registry_Number:
80-08-0

# ChEBI_ID:
4325

# Chemical_Formula:
C12H12N2O2S

# Chemical_IUPAC_Name:
4-[(4-aminobenzene)sulfonyl]aniline

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2041510

# Description:
A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)

# Dosage_Forms:
Tablet	Oral

# Drug_Category:
Anti-Infective Agents
Anti-Infectives
Anti-inflammatory Agents
Antimalarials
Antimycobacterials
Folic Acid Antagonists
Leprostatic Agents

# Drug_Interactions:
Aluminium	Formation of non-absorbable complexes
Calcium	Formation of non-absorbable complexes
Lumefantrine	Concomitant therapy may increase the risk of adverse hemolytic reactions. Monitor patients closely for symptoms of hemolytic reactions during concomitant therapy. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, methoglobulin reductase deficiency or hemoglobin M are at higher risk of experiencing hemolytic reactions.
Magnesium	Formation of non-absorbable complexes
Magnesium oxide	Formation of non-absorbable complexes
Rifabutin	Decreased levels of dapsone
Rifampin	Decreased levels of dapsone
Telithromycin	Telithromycin may reduce clearance of Dapsone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Dapsone if Telithromycin is initiated, discontinued or dose changed.
Tolbutamide	Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Dapsone. Consider alternate therapy or monitor for changes in Dapsone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.
Trimethoprim	Increased toxicity of both products
Voriconazole	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dapsone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of dapsone if voriconazole is initiated, discontinued or dose changed.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.97

# Experimental_Logs:
-2.82

# Experimental_Water_Solubility:
380 mg/L (at 37 °C)

# Food_Interactions:
Take without regard to meals.

# GenBank_ID:
Not Available

# Generic_Name:
Dapsone

# HET_ID:
Not Available

# Half_Life:
28 hours (range 10-50 hours)

# InChI_Identifier:
InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2

# InChI_Key:
InChIKey=MQJKPEGWNLWLTK-UHFFFAOYSA-N

# Indication:
For the treatment and management of leprosy and dermatitis herpetiformis.

# KEGG_Compound_ID:
C07666

# KEGG_Drug_ID:
D00592

# LIMS_Drug_ID:
250

# Mechanism_Of_Action:
Dapsone acts against bacteria and protozoa in the same way as sulphonamides, that is by inhibiting the synthesis of dihydrofolic acid through competition with para-amino-benzoate for the active site of dihydropteroate synthetase. The anti-inflammatory action of the drug is unrelated to its antibacterial action and is still not fully understood.

# Melting_Point:
175.5 °C

# Molecular_Weight_Avg:
248.301

# Molecular_Weight_Mono:
248.061948328

# Organisms_Affected:
Mycobacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA449211

# Pharmacology:
Dapsone is a sulfone with anti-inflammatory immunosuppressive properties as well as antibacterial and antibiotic properties. Dapsone is the principal drug in a multidrug regimen recommended by the World Health Organization for the treatment of leprosy. As an anti-infective agent, it is also used for treating malaria and, recently, for Pneumocystic carinii pneumonia in AIDS patients. Dapsone is absorbed rapidly and nearly completely from the gastrointestinal tract. Dapsone is distributed throughout total body water and is present in all tissues. However, it tends to be retained in skin and muscle and especially in the liver and kidney: traces of the drug are present in these organs up to 3 weeks after therapy cessation.

# Predicted_LogP_Hydrophobicity:
1.19

# Predicted_LogS:
-2.9

# Predicted_Water_Solubility:
2.84e-01 g/l

# Primary_Accession_No:
DB00250

# Protein_Binding:
70 to 90%

# PubChem_Compound_ID:
2955

# PubChem_Substance_ID:
46505300

# RxList_Link:
http://www.rxlist.com/cgi/generic/dapsone.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00345

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
1,1'-Sulfonylbis[4-aminobenzene]
4,4'-Diaminodiphenyl sulfone
4,4'-Diaminodiphenyl sulphone
4,4'-Diaminodiphenylsulfone
4,4'-Sulfonylbisbenzeneamine
4,4'-Sulfonyldianilin
4,4'-sulfonyldianiline
DDS, pharmaceutical

# Synthesis_Reference:
Not Available

# Toxicity:
Overdosage might be expected to produce nasal congestion, syncope, or hallucinations. Measures to support blood pressure should be taken if necessary.

# Update_Date:
2013-02-08 16:19:12 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Dapsone

# pKa_Isoelectric_Point:
2.41

# Phase_1_Metabolizing_Enzyme_10_Gene_Name:
FMO3

# Phase_1_Metabolizing_Enzyme_10_ID:
6101

# Phase_1_Metabolizing_Enzyme_10_Name:
Dimethylaniline monooxygenase [N-oxide-forming] 3

# Phase_1_Metabolizing_Enzyme_10_Protein_Sequence:
>Dimethylaniline monooxygenase [N-oxide-forming] 3
MGKKVAIIGAGVSGLASIRSCLEEGLEPTCFEKSNDIGGLWKFSDHAEEGRASIYKSVFS
NSSKEMMCFPDFPFPDDFPNFMHNSKIQEYIIAFAKEKNLLKYIQFKTFVSSVNKHPDFA
TTGQWDVTTERDGKKESAVFDAVMVCSGHHVYPNLPKESFPGLNHFKGKCFHSRDYKEPG
VFNGKRVLVVGLGNSGCDIATELSRTAEQVMISSRSGSWVMSRVWDNGYPWDMLLVTRFG
TFLKNNLPTAISDWLYVKQMNARFKHENYGLMPLNGVLRKEPVFNDELPASILCGIVSVK
PNVKEFTETSAIFEDGTIFEGIDCVIFATGYSFAYPFLDESIIKSRNNEIILFKGVFPPL
LEKSTIAVIGFVQSLGAAIPTVDLQSRWAAQVIKGTCTLPSMEDMMNDINEKMEKKRKWF
GKSETIQTDYIVYMDELSSFIGAKPNIPWLFLTDPKLAMEVYFGPCSPYQFRLVGPGQWP
GARNAILTQWDRSLKPMQTRVVGRLQKPCFFFHWLKLFAIPILLIAVFLVLT

# Phase_1_Metabolizing_Enzyme_10_SwissProt_ID:
P31513

# Phase_1_Metabolizing_Enzyme_11_Gene_Name:
NAT2

# Phase_1_Metabolizing_Enzyme_11_ID:
6102

# Phase_1_Metabolizing_Enzyme_11_Name:
Arylamine N-acetyltransferase 2

# Phase_1_Metabolizing_Enzyme_11_Protein_Sequence:
>Arylamine N-acetyltransferase 2
MDIEAYFERIGYKNSRNKLDLETLTDILEHQIRAVPFENLNMHCGQAMELGLEAIFDHIV
RRNRGGWCLQVNQLLYWALTTIGFQTTMLGGYFYIPPVNKYSTGMVHLLLQVTIDGRNYI
VDAGSGSSSQMWQPLELISGKDQPQVPCIFCLTEERGIWYLDQIRREQYITNKEFLNSHL
LPKKKHQKIYLFTLEPRTIEDFESMNTYLQTSPTSSFITTSFCSLQTPEGVYCLVGFILT
YRKFNYKDNTDLVEFKTLTEEEVEEVLKNIFKISLGRNLVPKPGDGSLTI

# Phase_1_Metabolizing_Enzyme_11_SwissProt_ID:
P11245

# Phase_1_Metabolizing_Enzyme_12_Gene_Name:
CYP2C18

# Phase_1_Metabolizing_Enzyme_12_ID:
6106

# Phase_1_Metabolizing_Enzyme_12_Name:
Cytochrome P450 2C18

# Phase_1_Metabolizing_Enzyme_12_Protein_Sequence:
>Cytochrome P450 2C18
MDPAVALVLCLSCLFLLSLWRQSSGRGRLPSGPTPLPIIGNILQLDVKDMSKSLTNFSKV
YGPVFTVYFGLKPIVVLHGYEAVKEALIDHGEEFSGRGSFPVAEKVNKGLGILFSNGKRW
KEIRRFCLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTNASPCDPTFILGCAPCNVICS
VIFHDRFDYKDQRFLNLMEKFNENLRILSSPWIQVCNNFPALIDYLPGSHNKIAENFAYI
KSYVLERIKEHQESLDMNSARDFIDCFLIKMEQEKHNQQSEFTVESLIATVTDMFGAGTE
TTSTTLRYGLLLLLKYPEVTAKVQEEIECVVGRNRSPCMQDRSHMPYTDAVVHEIQRYID
LLPTNLPHAVTCDVKFKNYLIPKGTTIITSLTSVLHNDKEFPNPEMFDPGHFLDKSGNFK
KSDYFMPFSAGKRMCMGEGLARMELFLFLTTILQNFNLKSQVDPKDIDITPIANAFGRVP
PLYQLCFIPV

# Phase_1_Metabolizing_Enzyme_12_SwissProt_ID:
P33260

# Phase_1_Metabolizing_Enzyme_13_Gene_Name:
CYP3A7

# Phase_1_Metabolizing_Enzyme_13_ID:
6107

# Phase_1_Metabolizing_Enzyme_13_Name:
Cytochrome P450 3A7

# Phase_1_Metabolizing_Enzyme_13_Protein_Sequence:
>Cytochrome P450 3A7
MDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNALSFRKGYWTF
DMECYKKYRKVWGIYDCQQPMLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKNAISI
AEDEEWKRIRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKHVFGAYS
MDVITSTSFGVSIDSLNNPQDPFVENTKKLLRFNPLDPFVLSIKVFPFLTPILEALNITV
FPRKVISFLTKSVKQIKEGRLKETQKHRVDFLQLMIDSQNSKDSETHKALSDLELMAQSI
IFIFAGYETTSSVLSFIIYELATHPDVQQKVQKEIDTVLPNKAPPTYDTVLQLEYLDMVV
NETLRLFPVAMRLERVCKKDVEINGMFIPKGVVVMIPSYVLHHDPKYWREPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALVNMKLALVRVLQNFSFKPCKETQIPLKLRFG
GLLLTEKPIVLKAESRDETVSGA

# Phase_1_Metabolizing_Enzyme_13_SwissProt_ID:
P24462

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
PTGS1

# Phase_1_Metabolizing_Enzyme_1_ID:
20

# Phase_1_Metabolizing_Enzyme_1_Name:
Prostaglandin G/H synthase 1

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Prostaglandin G/H synthase 1 precursor
MSRSLLLRFLLFLLLLPPLPVLLADPGAPTPVNPCCYYPCQHQGICVRFGLDRYQCDCTR
TGYSGPNCTIPGLWTWLRNSLRPSPSFTHFLLTHGRWFWEFVNATFIREMLMRLVLTVRS
NLIPSPPTYNSAHDYISWESFSNVSYYTRILPSVPKDCPTPMGTKGKKQLPDAQLLARRF
LLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDNLERQ
YQLRLFKDGKLKYQVLDGEMYPPSVEEAPVLMHYPRGIPPQSQMAVGQEVFGLLPGLMLY
ATLWLREHNRVCDLLKAEHPTWGDEQLFQTTRLILIGETIKIVIEEYVQQLSGYFLQLKF
DPELLFGVQFQYRNRIAMEFNHLYHWHPLMPDSFKVGSQEYSYEQFLFNTSMLVDYGVEA
LVDAFSRQIAGRIGGGRNMDHHILHVAVDVIRESREMRLQPFNEYRKRFGMKPYTSFQEL
VGEKEMAAELEELYGDIDALEFYPGLLLEKCHPNSIFGESMIEIGAPFSLKGLLGNPICS
PEYWKPSTFGGEVGFNIVKTATLKKLVCLNTKTCPYVSFRVPDASQDDGPAVERPSTEL

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P23219

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
PTGS2

# Phase_1_Metabolizing_Enzyme_2_ID:
290

# Phase_1_Metabolizing_Enzyme_2_Name:
Prostaglandin G/H synthase 2

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Prostaglandin G/H synthase 2 precursor
MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL
TRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY
GYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS
NMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY
QIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD
VLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ
NRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV
AGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL
YGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV
GFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER
STEL

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P35354

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
MPO

# Phase_1_Metabolizing_Enzyme_3_ID:
1757

# Phase_1_Metabolizing_Enzyme_3_Name:
Myeloperoxidase

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Myeloperoxidase precursor
MGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTS
LVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLH
VALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMC
NNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTD
QLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPND
PRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQL
GLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLL
REHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYR
SYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLE
GGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYN
AWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPL
LACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMS
NSYPRDFVNCSTLPALNLASWREAS

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P05164

# Phase_1_Metabolizing_Enzyme_4_Gene_Name:
CYP3A5

# Phase_1_Metabolizing_Enzyme_4_ID:
4118

# Phase_1_Metabolizing_Enzyme_4_Name:
Cytochrome P450 3A5

# Phase_1_Metabolizing_Enzyme_4_Protein_Sequence:
>Cytochrome P450 3A5
MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF
DTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL
AEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS
MDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL
FPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI
IFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV
NETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS
KKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG
LLQPEKPIVLKVDSRDGTLSGE

# Phase_1_Metabolizing_Enzyme_4_SwissProt_ID:
P20815

# Phase_1_Metabolizing_Enzyme_5_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_5_ID:
4512

# Phase_1_Metabolizing_Enzyme_5_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_5_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_5_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_6_Gene_Name:
CYP2C9

# Phase_1_Metabolizing_Enzyme_6_ID:
4757

# Phase_1_Metabolizing_Enzyme_6_Name:
Cytochrome P450 2C9

# Phase_1_Metabolizing_Enzyme_6_Protein_Sequence:
>Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_6_SwissProt_ID:
P11712

# Phase_1_Metabolizing_Enzyme_7_Gene_Name:
CYP2C8

# Phase_1_Metabolizing_Enzyme_7_ID:
4924

# Phase_1_Metabolizing_Enzyme_7_Name:
Cytochrome P450 2C8

# Phase_1_Metabolizing_Enzyme_7_Protein_Sequence:
>Cytochrome P450 2C8
MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV
YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW
KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS
VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT
RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE
TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD
LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK
KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP
PSYQICFIPV

# Phase_1_Metabolizing_Enzyme_7_SwissProt_ID:
P10632

# Phase_1_Metabolizing_Enzyme_8_Gene_Name:
CYP2E1

# Phase_1_Metabolizing_Enzyme_8_ID:
6013

# Phase_1_Metabolizing_Enzyme_8_Name:
Cytochrome P450 2E1

# Phase_1_Metabolizing_Enzyme_8_Protein_Sequence:
>Cytochrome P450 2E1
MSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLELKNIPKSFTRL
AQRFGPVFTLYVGSQRMVVMHGYKAVKEALLDYKDEFSGRGDLPAFHAHRDRGIIFNNGP
TWKDIRRFSLTTLRNYGMGKQGNESRIQREAHFLLEALRKTQGQPFDPTFLIGCAPCNVI
ADILFRKHFDYNDEKFLRLMYLFNENFHLLSTPWLQLYNNFPSFLHYLPGSHRKVIKNVA
EVKEYVSERVKEHHQSLDPNCPRDLTDCLLVEMEKEKHSAERLYTMDGITVTVADLFFAG
TETTSTTLRYGLLILMKYPEIEEKLHEEIDRVIGPSRIPAIKDRQEMPYMDAVVHEIQRF
ITLVPSNLPHEATRDTIFRGYLIPKGTVVVPTLDSVLYDNQEFPDPEKFKPEHFLNENGK
FKYSDYFKPFSTGKRVCAGEGLARMELFLLLCAILQHFNLKPLVDPKDIDLSPIHIGFGC
IPPRYKLCVIPRS

# Phase_1_Metabolizing_Enzyme_8_SwissProt_ID:
P05181

# Phase_1_Metabolizing_Enzyme_9_Gene_Name:
CYP2C19

# Phase_1_Metabolizing_Enzyme_9_ID:
6016

# Phase_1_Metabolizing_Enzyme_9_Name:
Cytochrome P450 2C19

# Phase_1_Metabolizing_Enzyme_9_Protein_Sequence:
>Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_9_SwissProt_ID:
P33261

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10439322	Gillis TP, Williams DL: Dapsone resistance does not appear to be associated with a mutation in the dihydropteroate synthase-2 gene of Mycobacterium leprae. Indian J Lepr. 1999 Jan-Mar;71(1):11-8.
10817704	Williams DL, Spring L, Harris E, Roche P, Gillis TP: Dihydropteroate synthase of Mycobacterium leprae and dapsone resistance. Antimicrob Agents Chemother. 2000 Jun;44(6):1530-7.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
18680522	Gengenbacher M, Xu T, Niyomrattanakit P, Spraggon G, Dick T: Biochemical and structural characterization of the putative dihydropteroate synthase ortholog Rv1207 of Mycobacterium tuberculosis. FEMS Microbiol Lett. 2008 Oct;287(1):128-35. Epub 2008 Aug 1.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
U15180

# Drug_Target_1_GenBank_ID_Protein:
699152

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
folP2

# Drug_Target_1_Gene_Sequence:
>876 bp
GTGCAGTCAATGCTGTGCGGCCGGCCGGTCGCAGCGGATCGCCAACTGATCATGGCGATC
GTCAACCGTACCCCGGATTCGTTCTATGACCGGGGCGCGACCTTCAGTGACGAGGCTGCT
CGTGCTGCAGCGCACCGGGCCGTTGCGGAGGGCGCCGATGTCATCGATGTCGGCGGCGTT
AAAGCAGGGCCTGGTCAGGGCGTTGACGTAGACACCGAGATCGCCCGGTTGGTTCCGTTC
ATCGAATGGCTACGCAGCGCCTATACAGACCTGCTGATCAGCGTAGACACCTGGCGAGCA
GAGGTAGCAAGACTGGCTTGCACTGCGGGCGCAGACCTGATCAACGACAGCTGGGGTGGA
GCCGACCCGGCCATGCATGAGGTCGCCGCTGAGCTTGGCGCGGGCCTGGTGTGTTCGCAC
ACCGGTGGCGCGCTGCCCCGCACGCGTCCCTTTCGGGTGAGTTACGGTACGACGACCCGC
GGTGTGGTGGACGATGTGATTCGCCAGGTCACTGCAGCTGCCGAGCGCGCGGTCGCGGCC
GGGGTAACCCGCGATTCGGTGTTGGTCGACCCGACCCACGATTTCGGCAAGAACACTTTC
CACGGGCTGCTGCTGTTGCGTCATGTAGACGAACTTGTTAAGACCGGGTGGCCCGTGCTC
ATGTCGTTGAGCAATAAGGACTTCGTCGGGGAGACTCTGGGCGTGGGTTTGACGGAACGG
CTAGAGGGTACGTTGGCGGCCACTGCGTTGGCGGCGGCAGCTGGCGTCCGCATGTTTCGG
GTGCACGAGGTCGTAGCGACCAGGCGGGTTCTGGAGATGGTGGCTTCGATCCAGGGGACG
CGTCCCCCAACGCGCACGGTGAGGGGACTCGCATGA

# Drug_Target_1_General_Function:
Coenzyme transport and metabolism

# Drug_Target_1_General_References:
11234002	Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, Honore N, Garnier T, Churcher C, Harris D, Mungall K, Basham D, Brown D, Chillingworth T, Connor R, Davies RM, Devlin K, Duthoy S, Feltwell T, Fraser A, Hamlin N, Holroyd S, Hornsby T, Jagels K, Lacroix C, Maclean J, Moule S, Murphy L, Oliver K, Quail MA, Rajandream MA, Rutherford KM, Rutter S, Seeger K, Simon S, Simmonds M, Skelton J, Squares R, Squares S, Stevens K, Taylor K, Whitehead S, Woodward JR, Barrell BG: Massive gene decay in the leprosy bacillus. Nature. 2001 Feb 22;409(6823):1007-11.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3808

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
30852

# Drug_Target_1_Name:
Dihydropteroate synthase 2

# Drug_Target_1_Number_of_Residues:
291

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00809	Pterin_bind

# Drug_Target_1_Protein_Sequence:
>Dihydropteroate synthase 2
MQSMLCGRPVAADRQLIMAIVNRTPDSFYDRGATFSDEAARAAAHRAVAEGADVIDVGGV
KAGPGQGVDVDTEIARLVPFIEWLRSAYTDLLISVDTWRAEVARLACTAGADLINDSWGG
ADPAMHEVAAELGAGLVCSHTGGALPRTRPFRVSYGTTTRGVVDDVIRQVTAAAERAVAA
GVTRDSVLVDPTHDFGKNTFHGLLLLRHVDELVKTGWPVLMSLSNKDFVGETLGVGLTER
LEGTLAATALAAAAGVRMFRVHEVVATRRVLEMVASIQGTRPPTRTVRGLA

# Drug_Target_1_Reaction:
2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine diphosphate + 4-aminobenzoate = diphosphate + dihydropteroate

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
DHPS catalyzes the formation of the immediate precursor of folic acid. It is implicated in resistance to sulfonamide

# Drug_Target_1_SwissProt_ID:
P0C0X2

# Drug_Target_1_SwissProt_Name:
DHPS2_MYCLE

# Drug_Target_1_Synonyms:
DHPS 2
Dihydropteroate pyrophosphorylase 2
EC 2.5.1.15

# Drug_Target_1_Theoretical_pI:
6.40

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10817704	Williams DL, Spring L, Harris E, Roche P, Gillis TP: Dihydropteroate synthase of Mycobacterium leprae and dapsone resistance. Antimicrob Agents Chemother. 2000 Jun;44(6):1530-7.
11454253	Lee SB, Kim SK, Kang TJ, Chae GT, Chun JH, Shin HK, Kim JP, Ko YH, Kim NH: The prevalence of folP1 mutations associated with clinical resistance to dapsone, in Mycobacterium leprae isolates from South Korea. Ann Trop Med Parasitol. 2001 Jun;95(4):429-32.
16355335	Cambau E, Carthagena L, Chauffour A, Ji B, Jarlier V: Dihydropteroate synthase mutations in the folP1 gene predict dapsone resistance in relapsed cases of leprosy. Clin Infect Dis. 2006 Jan 15;42(2):238-41. Epub 2005 Dec 12.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
18680522	Gengenbacher M, Xu T, Niyomrattanakit P, Spraggon G, Dick T: Biochemical and structural characterization of the putative dihydropteroate synthase ortholog Rv1207 of Mycobacterium tuberculosis. FEMS Microbiol Lett. 2008 Oct;287(1):128-35. Epub 2008 Aug 1.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
AB028658

# Drug_Target_2_GenBank_ID_Protein:
5832717

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
folP1

# Drug_Target_2_Gene_Sequence:
>855 bp
GTGAGTTTGGCGCCAGTGCAGGTTATTGGGGTTTTGAACGTCACTGACAATTCGTTCTCA
GATGGCGGACGTTACCTTGATCCTGATGATGCTGTCCAGCACGGCCTGGCAATGGTCGCG
GAAGGCGCGGCGATTGTCGACGTCGGTGGCGAATCGACCCGGCTCGGTGCCATTAGGACC
GATCCTCGAGTTGAACTCTCTCGTATCGTTCCTGTCGTAAAAGAACTTGCAGCACAGGGG
ATTACAGTAAGTATCGATACTACGCGCGCTGATGTTGCACGGGCGGCGCTGCAAAGCGGC
GCACGGATCGTCAACGATGTGTCTGGTGGGCGAGCAGATCCCGCGATGGCTCCTCTGGTG
GCTGAAGCCGGTGTTGCGTGGGTGTTGATGCACTGGCGACTGATGTCGGCTGAACGGCCG
TATGAGGCTCCGAATTACCGCGACGTGGTGGCTGAAGTGCGTGCCGACCTACTGGCTGGT
GTCGATCAGGCTGTGGCCGCAGGTGTTGATCCTGGGAGTCTAGTGATCGATCCCGGGCTT
GGATTCGCCAAGACGGGACAGCACAATTGGGCGCTGCTGAATGCGTTACCGGAGTTGGTG
GCTACTGGGGTCCCGATTCTACTTGGCGCCTCGCGTAAACGGTTCCTGGGTAGGTTATTA
GCTGGGGCTGATGGCGCGGTACGACCGCCGGACGGACGTGAGACGGCGACCGCGGTGATT
TCCGCACTTGCTGCCCTACACGGGGCTTGGGGTGTTCGGGTGCACGATGTGCGTGCCTCG
GTCGACGCACTCAAGGTCGTCGGGGCTTGGCTGCATGCTGGGCCGCAGATTGAAAAGGTT
AGATGTGATGGCTGA

# Drug_Target_2_General_Function:
Coenzyme transport and metabolism

# Drug_Target_2_General_References:
10474189	Kai M, Matsuoka M, Nakata N, Maeda S, Gidoh M, Maeda Y, Hashimoto K, Kobayashi K, Kashiwabara Y: Diaminodiphenylsulfone resistance of Mycobacterium leprae due to mutations in the dihydropteroate synthase gene. FEMS Microbiol Lett. 1999 Aug 15;177(2):231-5.
10542185	Nopponpunth V, Sirawaraporn W, Greene PJ, Santi DV: Cloning and expression of Mycobacterium tuberculosis and Mycobacterium leprae dihydropteroate synthase in Escherichia coli. J Bacteriol. 1999 Nov;181(21):6814-21.
11234002	Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, Honore N, Garnier T, Churcher C, Harris D, Mungall K, Basham D, Brown D, Chillingworth T, Connor R, Davies RM, Devlin K, Duthoy S, Feltwell T, Fraser A, Hamlin N, Holroyd S, Hornsby T, Jagels K, Lacroix C, Maclean J, Moule S, Murphy L, Oliver K, Quail MA, Rajandream MA, Rutherford KM, Rutter S, Seeger K, Simon S, Simmonds M, Skelton J, Squares R, Squares S, Stevens K, Taylor K, Whitehead S, Woodward JR, Barrell BG: Massive gene decay in the leprosy bacillus. Nature. 2001 Feb 22;409(6823):1007-11.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3807

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
29448

# Drug_Target_2_Name:
Dihydropteroate synthase 1

# Drug_Target_2_Number_of_Residues:
284

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00809	Pterin_bind

# Drug_Target_2_Protein_Sequence:
>Dihydropteroate synthase 1
MSLAPVQVIGVLNVTDNSFSDGGRYLDPDDAVQHGLAMVAEGAAIVDVGGESTRPGAIRT
DPRVELSRIVPVVKELAAQGITVSIDTTRADVARAALQSGARIVNDVSGGRADPAMAPLV
AEAGVAWVLMHWRLMSAERPYEAPNYRDVVAEVRADLLAGVDQAVAAGVDPGSLVIDPGL
GFAKTGQHNWALLNALPELVATGVPILLGASRKRFLGRLLAGADGAVRPPDGRETATAVI
SALAALHGAWGVRVHDVRASVDALKVVGAWLHAGPQIEKVRCDG

# Drug_Target_2_Reaction:
2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine diphosphate + 4-aminobenzoate = diphosphate + dihydropteroate

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
DHPS catalyzes the formation of the immediate precursor of folic acid. It is implicated in resistance to sulfonamide

# Drug_Target_2_SwissProt_ID:
P0C0X1

# Drug_Target_2_SwissProt_Name:
DHPS1_MYCLE

# Drug_Target_2_Synonyms:
DHPS 1
Dihydropteroate pyrophosphorylase 1
EC 2.5.1.15

# Drug_Target_2_Theoretical_pI:
5.63

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB00250
